Elevated glucose levels can acetylate Rictor in an acetyl‐CoA‐dependent manner through the glycolytic pathway, and acetylated Rictor can maintain mTORC2 self‐activation, thereby reducing the sensitivity of glioblastoma cells to PI3K/AKT‐targeted therapy. The gene discussed is AKT1; the disease is glioblastoma.